Skip to main content
Testing version — LOERadar is in active testing. Features and data may change.
LOERadar
LOE
Radar
Hub
News
Changes
Search
Log in
Get Started
AQNEURSA (LEVACETYLLEUCINE) | LOERadar
Viewing data from:
Latest
2026-07-01
2026-06-01
2026-05-01
2026-04-01
2026-03-28
2026-02-17
2026-02-10
2025-12-14
2025-02-26
2025-01-25
2024-11-08
2023-07-23
2023-06-15
2023-05-13
2023-01-26
2022-11-22
2022-10-28
2022-09-29
2022-07-09
2022-06-29
2022-04-08
2022-03-09
2021-12-28
2021-05-05
2021-03-12
2020-12-22
2020-11-12
2019-12-14
2019-09-15
AQNEURSA
NDA
Get alerts
LEVACETYLLEUCINE | N219132 | INTRABIO INC
1 strength
3 unique patents
2 unique exclusivities
Patents
SEC Intel
Revenue
PTAB
Reexams
Litigation
Petitions
Trials
Approvals
Label
Products
Patent Timeline
3 unique patents, 2 exclusivities by expiration date
Active (3)
Today
Exclusivity
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
Today
11400067
Apr. 19, 2037
12433862
Apr. 19, 2037
12433863
Apr. 19, 2037
NCE
Sep. 24, 2029
ODE-498
Sep. 24, 2031
PTAB Proceedings
No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board
Hatch-Waxman Litigation
No ANDA patent litigation cases (NOS 835) matched from PACER
Citizen Petitions
No FDA citizen petitions matched from Regulations.gov
Products (1)
#001 — 1GM/PACKET
RLD
3 patents
2 exclusivities
▴
FOR SUSPENSION;ORAL | Approved: Sep 24, 2024
Patents (3)
Patent #
Expiration
PED
Drug Substance
Drug Product
Use Code
Delist
11400067
Apr 19, 2037
—
—
—
U-4170
USE OF LEVACETYLLEUCINE FOR TREATMENT OF NEUROLOGICAL MANIFESTATIONS OF NIEMANN-PICK DISEASE TYPE-C (NPC)
—
12433862
Apr 19, 2037
—
—
—
U-4284
TREATMENT OF NEUROLOGICAL MANIFESTATIONS OF NIEMANN-PICK DISEASE TYPE-C (NPC) FOR A DURATION OF GREATER THAN 3 MONTHS
—
12433863
Apr 19, 2037
—
—
—
U-4285
TREATMENT OF NEUROLOGICAL MANIFESTATIONS OF NIEMANN-PICK DISEASE TYPE-C (NPC) FOR A DURATION OF AT LEAST ABOUT 3 MONTHS
—
Exclusivities (2)
Code
Date
Status
NCE
Sep 24, 2029
Active
ODE-498
Sep 24, 2031
Active